Retension Pharmaceuticals Inc. (RTSN) P/E Ratio, ROE & Key Statistics
$11.41NASDAQ: RTSNMarket Cap $42.79M
Data as of Nov 17, 2026 close · Source: Financial Modeling Prep (methodology)
Every valuation, profitability, balance-sheet and per-share figure DeltaScreener holds for Retension Pharmaceuticals Inc. (RTSN), each with what it measures. Figures are trailing twelve months or the most recent reported period.
Valuation
Metric
Value
P/E ratioShare price divided by earnings per share.
-5.16
Earnings yieldEarnings per share as a percentage of the share price — the inverse of P/E.
-18.55%
Profitability
Metric
Value
Gross marginRevenue left after the direct cost of goods sold.
0.00%
Operating marginRevenue left after operating costs.
0.00%
Net marginRevenue left after every cost, including tax and interest.
0.00%
Financial health
Metric
Value
Current ratioCurrent assets divided by current liabilities. Above 1 means short-term assets cover short-term bills.
5.61
Quick ratioThe same, excluding inventory.
4.69
Per share and size
Metric
Value
Earnings per shareProfit attributable to each share.
−$2.78
Book value per shareShareholders’ equity divided by shares outstanding.
−$18.48
Market capitalisationShare price times shares outstanding.
$42.79M
Dividend
Metric
Value
Dividend yieldAnnual dividend as a percentage of the share price.
0.00%
Retension Pharmaceuticals Inc. (RTSN) statistics — frequently asked questions
What is Retension Pharmaceuticals Inc.'s P/E ratio?
Retension Pharmaceuticals Inc. (RTSN) trades on a price-to-earnings ratio of -5.16. A negative P/E means the company reported a loss, so the ratio is not a meaningful valuation measure.
How much debt does Retension Pharmaceuticals Inc. carry?
Retension Pharmaceuticals Inc. (RTSN) has a debt-to-equity ratio of 0.00, which compares total borrowings with shareholders' equity.
P/E and ROE of other Medical - Pharmaceuticals stocks